aid: asieris
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/asieris.png
name: asieris
description: Asieris Pharmaceuticals is a China-based biopharmaceutical company developing innovative
  therapies in genitourinary tumors and women's health. Its focus areas span urologic oncology (bladder
  cancer diagnosis and treatment), women's health, and breast and gynecologic oncology, with marquee
  assets Vesique (APL-1202) for bladder cancer and Cevira (APL-1702), a non-invasive photodynamic therapy
  for cervical precancerous lesions. The company runs three proprietary R&D platforms (TIMN, TAIDD, DDC).
  It was surfaced as a portfolio company of Qiming and added to the API Evangelist network; as a
  biopharma company it publishes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/asieris/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Healthcare
- Oncology
- Women's Health
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/asieris-domain-security.yml
- type: Website
  url: https://asieris.cn
- type: Website
  name: Asieris (English)
  url: https://asieris.com/
- type: About
  url: https://asieris.com/about/
- type: Support
  name: Contact
  url: https://asieris.com/contact/
- type: Blog
  name: News
  url: https://asieris.com/news/
- type: PrivacyPolicy
  url: https://asieris.com/privacy-policy/
- type: TermsOfService
  url: https://asieris.com/termsuse/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence